menu
    • menu
    [{"orgOrder":0,"company":"selectION","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SI-544","moa":"Kv1.3","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"selectION \/ FGK Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ FGK Clinical Research"},{"orgOrder":0,"company":"selectION","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SI-544","moa":"Kv1.3","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"selectION \/ FGK Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ FGK Clinical Research"},{"orgOrder":0,"company":"selectION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"si-544","moa":"Kv1.3","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"selectION \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by selectION

    Menu

    selectION

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            selectION

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            selectION

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SI-544

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris ...

                            Details : SI-544 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 05, 2024

                            Lead Product(s) : SI-544

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            selectION

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            selectION

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : si-544

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SelectION Reports Safety Results from SAD Stage of SI-544 Phase Ib trial

                            Details : si-544, the Company´s drug candidate, is blocking Kv1.3, a specific ion channel involved in the activation and proliferation of TEM cells. It is being developed in Phase 1 trial in atopic dermatitis patients.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 30, 2023

                            Lead Product(s) : si-544

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            selectION

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            selectION

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SI-544

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Derm...

                            Details : SI-544 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : SI-544

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth